









市場行情
/
股票
/
nasdaq-mnpr
/

Monopar Therapeutics Inc

MNPR

68.770USD

-2.010-2.84%

收盤 12/26, 16:00（美東）報價延遲15分鐘

458.21M總市值

虧損本益比TTM



Monopar Therapeutics Inc

68.770

-2.010-2.84%

概覽公司財務分析

概覽

公司

財務

分析

關於 Monopar Therapeutics Inc 公司

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Monopar Therapeutics Inc簡介



公司代碼MNPR

公司名稱Monopar Therapeutics Inc

上市日期Dec 19, 2019

CEORobinson (Chandler D)

員工數量16

證券類型Ordinary Share

年結日Dec 19

公司地址1000 Skokie Blvd Ste 350

城市WILMETTE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編60091-1146

電話18473880349

網址https://www.monopartx.com/

公司代碼MNPR

上市日期Dec 19, 2019

CEORobinson (Chandler D)

Monopar Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Chandler D. Robinson, M.D.

Chief Executive Officer, Director

79.42K

+8.10%

Dr. Christopher M. (Chris) Starr, Ph.D.

Executive Chairman of the Board

16.05K

Ms. Lavina Talukdar

Independent Director

14.00K

Ms. Kim R. Tsuchimoto

Director

11.49K

Mr. Arthur J. Klausner

Independent Director

6.17K

Mr. Raymond William (Bill) Anderson

Independent Director

5.37K

Mr. Vu Quan

Chief Financial Officer, Principal Accounting Officer

Dr. Patrice P. Rioux, M.D., Ph.D.

Acting Chief Medical Officer

Mr. Andrew J. Cittadine

Chief Operating Officer

名稱

名稱/職務

職務

持股

持股變動

Dr. Chandler D. Robinson, M.D.

Chief Executive Officer, Director

79.42K

+8.10%

Dr. Christopher M. (Chris) Starr, Ph.D.

Executive Chairman of the Board

16.05K

Ms. Lavina Talukdar

Independent Director

14.00K

Ms. Kim R. Tsuchimoto

Director

11.49K

Mr. Arthur J. Klausner

Independent Director

6.17K

Mr. Raymond William (Bill) Anderson

Independent Director

5.37K

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

Janus Henderson Investors

19.26%

Adage Capital Management, L.P.

9.86%

Gem Pharmaceuticals LLC

9.14%

RA Capital Management, LP

7.65%

AstraZeneca PLC

5.80%

其他

48.28%

持股股東

佔比

Janus Henderson Investors

19.26%

Adage Capital Management, L.P.

9.86%

Gem Pharmaceuticals LLC

9.14%

RA Capital Management, LP

7.65%

AstraZeneca PLC

5.80%

其他

48.28%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

27.20%

Hedge Fund

19.02%

Corporation

19.01%

Investment Advisor

9.43%

Venture Capital

9.00%

Individual Investor

4.78%

Research Firm

0.24%

Pension Fund

0.07%

Bank and Trust

0.06%

其他

11.17%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

3.34M

50.46%

+135.23K

2025Q2

5.07M

82.91%

-355.61K

2025Q1

5.03M

83.96%

+455.96K

2024Q4

4.84M

79.28%

+1.76M

2024Q3

1.90M

50.69%

+25.14K

2024Q2

1.96M

52.51%

+123.52K

2024Q1

1.91M

52.92%

+136.66K

2023Q4

1.88M

67.20%

+125.61K

2023Q3

1.87M

67.45%

+153.91K

2023Q2

1.84M

66.75%

+138.58K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Janus Henderson Investors

1.17M

17.73%

+37.96K

+3.35%

Jun 30, 2025

Adage Capital Management, L.P.

599.20K

9.06%

Jun 30, 2025

Gem Pharmaceuticals LLC

611.08K

9.24%

Apr 04, 2025

RA Capital Management, LP

511.21K

7.73%

Jun 30, 2025

AstraZeneca PLC

387.33K

5.86%

+387.33K

Oct 23, 2024

Tactic Pharma LLC

272.03K

4.11%

-550.23K

-66.92%

Sep 24, 2025

The Vanguard Group, Inc.

86.49K

1.31%

+31.25K

+56.59%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

183.97K

2.78%

+175.22K

+2003.49%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

iShares Micro-Cap ETF

0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.05%

Vanguard US Momentum Factor ETF

0.04%

iShares Russell 2000 Growth ETF

0.02%

Proshares Ultra Russell 2000

0.01%

Global X Russell 2000 ETF

0.01%

ProShares Hedge Replication ETF

0.01%

ProShares UltraPro Russell2000

0.01%

iShares Russell 2000 ETF

0.01%

Avantis US Small Cap Equity ETF

iShares Micro-Cap ETF

佔比0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0.05%

Vanguard US Momentum Factor ETF

佔比0.04%

iShares Russell 2000 Growth ETF

佔比0.02%

Proshares Ultra Russell 2000

佔比0.01%

Global X Russell 2000 ETF

佔比0.01%

ProShares Hedge Replication ETF

佔比0.01%

ProShares UltraPro Russell2000

佔比0.01%

iShares Russell 2000 ETF

佔比0.01%

Avantis US Small Cap Equity ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

公告日期

類型

比率

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

常見問題

Monopar Therapeutics Inc的前五大股東是誰？



Monopar Therapeutics Inc的前五大股東如下：
Janus Henderson Investors
持有股份：1.17M
佔總股份比例：17.73%。
Adage Capital Management, L.P.
持有股份：599.20K
佔總股份比例：9.06%。
Gem Pharmaceuticals LLC
持有股份：611.08K
佔總股份比例：9.24%。
RA Capital Management, LP
持有股份：511.21K
佔總股份比例：7.73%。
AstraZeneca PLC
持有股份：387.33K
佔總股份比例：5.86%。